Xiao1 Y, Zhang S, Dai N, et al. - A phase III, double-blind, multicentre study was conducted to determine the non-inferior utility of vonoprazan vs lansoprazole in the treatment of Asian patients with erosive oesophagitis (EO). They randomized endoscopically confirmed EO individuals to receive vonoprazan 20 mg or lansoprazole 30 mg, once daily for up to 8 weeks. 8-week EO healing rates were 92.4% and 91.3% respectively, in the vonoprazan and lansoprazole arms. In comparison with lansoprazole, it was noted that EO healing rates appeared higher with vonoprazan. 38.1% and 36.6% treatment-emergent adverse events rates were noted in the vonoprazan and lansoprazole group, respectively. The results indicated the non-inferior utility of vonoprazan versus lansoprazole in terms of EO healing rate at 8 weeks in this population. Similar safety outcomes were found in the two treatment arms.